Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better
Summary
Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. Its lead asset is in development under a partnership with Takeda Pharmaceutical (NYSE: TAK), and now the biotech has $118 million more to advance additional compounds to human testing. From operations in Research Triangle Park, NC, and Austin, TX, Shattuck is developing drugs intended to offer a multi-pronged approach to cancer, CEO Taylor Schreiber says. In preclinical studies, Shattuck reports that this combination enhanced the proliferation of T cells and the increased the production of signaling molecules that play a role in the immune response to cancer. Early clinical trial results from that biotech’s lead drug were so encouraging that Gilead Sciences (NASDAQ: GILD) shelled out $4.9 billion to buy the company.
Classifications
AskAI Classifications
LabelsLinked Companies
